文献速递肾移植肾小球疾病

复发性与新生IgA肾病肾移植结局比较

Kidney Transplant Outcomes in Recurrent Versus De Novo IgA Nephropathy.
PubMed 文献 · Kidney Int Rep · 2025-05-21

该回顾性研究分析了264例伴肾小球IgA沉积的肾移植活检,区分复发性与新发IgA肾病,比较两组临床病理特征并分析移植肾存活相关因素。复发性IgA肾病活检中M1、E1、新月体及C3>1+比例更高;复发性患者活检时血肌酐高、蛋白尿及Oxford E/T/C评分>0、C3>1+与移植肾丢失相关。

要点

  • 复发性IgA肾病活检较新发者更常见系膜细胞增生、内皮细胞增生、新月体及C3>1+沉积。
  • 复发性IgA肾病患者活检时血肌酐升高和蛋白尿与移植肾丢失风险增加相关。
  • 复发性IgA肾病活检Oxford E、T、C评分>0及C3>1+与移植肾丢失风险增加相关。

核心结论

  • 研究提示对疑似复发性IgA肾病患者应重视蛋白尿检测,并对活检采用Oxford MEST-C评分。

研究设计与样本

  • 回顾性分析264例伴肾小球IgA沉积的肾移植活检,尽可能区分复发性与新发IgA肾病,比较两组临床与病理特征。
  • 对有随访的复发性IgA肾病患者分析移植肾结局,识别与移植肾存活相关的发现。

主要发现

  • 复发性IgA肾病活检(n=127)较新发IgA肾病活检(n=46)更常见系膜细胞增生(M1)、内皮细胞增生(E1)、新月体(C1-2)及肾小球C3染色>1+(0-4+量表)。
  • 复发性与新发IgA肾病活检在Oxford S和T评分及活检时平均移植后时间方面无显著差异。
  • 19例供者来源IgA沉积的活检均无任何MEST-C评分>0或C3染色>1+。
  • 54例有随访的复发性IgA肾病患者中,25例在活检后2至109个月间丢失移植肾。
  • 活检时血肌酐和蛋白尿较高、Oxford E、T、C评分>0及C3>1+与移植肾丢失风险增加显著相关。

临床怎么用

  • 作者认为对疑似复发性IgA肾病患者应检测蛋白尿,并对活检采用Oxford MEST-C评分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: IgA nephropathy (IgAN) recurs frequently in kidney transplants, although the reported frequency of recurrence varies because many studies do not distinguish recurrent IgAN from IgAN occurring de novo in the allograft. In addition, there are only limited studies of graft outcomes in patients with recurrent IgAN. METHODS: We retrospectively examined 264 kidney transplant biopsies with glomerular IgA deposits, distinguishing whenever possible recurrent versus de novo IgAN, and compared clinical and pathologic features of biopsies of patients within these groups. We also examined graft outcomes in patients with available follow-up to identify findings associated with graft survival. RESULTS: A significantly greater fraction of biopsies with recurrent disease (n = 127) had mesangial (M1) and endocapillary (E1) hypercellularity, crescents (C1-2), and > 1+ (0-4+ scale) glomerular C3 staining than biopsies with de novo (n = 46) IgAN; there was no significant difference between these groups with respect to Oxford S and T scores, or mean time posttransplantation of the biopsy. None of 19 biopsies with IgA deposits attributable to the donor had any MEST-C scores > 0 or C3 staining > 1+. Of 54 patients with recurrent IgAN and follow-up, 25 lost their grafts between 2 and 109 months postbiopsy. Findings at the time of biopsy significantly associated with an increased risk of graft loss in patients were higher serum creatinine (SCr) and proteinuria; Oxford E, T, and C scores > 0; and C3 > 1+. CONCLUSION: The findings indicate the importance of measuring proteinuria in patients with suspected recurrent IgAN and scoring such biopsies using the Oxford MEST-C scores.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Haas M, Mirocha J, Grace Choung HY, et al. Kidney Transplant Outcomes in Recurrent Versus De Novo IgA Nephropathy. Kidney Int Rep. 2025. PMID: 40814608. doi:10.1016/j.ekir.2025.05.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。